Bone Health

Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study

January 26th 2023

By Skylar Jeremias

Saudi Arabia approved an adalimumab biosimilar, a denosumab biosimilar entered the market in the Republic of Korea, and Dr. Reddy’s Laboratories announced the completion of a phase 3 study for its rituximab biosimilar.

Study: Denosumab Biosimilar Looks Promising for Osteoporosis in Phase 3 Trial

January 18th 2023

By Justina Petrullo

Article

Researchers found that a denosumab biosimilar appeared comparably safe and effective to reference drug Prolia.

Biosimilar Check-in: PBM to Cover Adalimumab Biosimilars; World’s First Denosumab Biosimilar; Organon Launches in Canada

November 17th 2022

By Skylar Jeremias

Article

Organon Canada launches 2 biosimilars referencing Avastin (bevacizumab) and Herceptin (trastuzumab), China became the first country to approve a denosumab biosimilar, and Optum Rx, a large pharmacy benefit manager (PBM), said that it will add adalimumab biosimilars to formulary.

Biosimilar Business News Recap: Mepolizumab Study; New Licensing Deal; Hukyndra Launches in Switzerland

October 18th 2022

By Skylar Jeremias

Article

Bio-Thera Solutions began a phase 1 trial for its mepolizumab biosimilar candidate; Biocon Biologics licenses out 2 biosimilars to Yoshindo; and Alvotech and STADA Arzneimittel launch Hukyndra, an adalimumab biosimilar, in Switzerland.

Eye on Pharma: 2 US Launches, an EMA Filing, and Denosumab Results

October 6th 2022

By Skylar Jeremias

Article

Recently, the US got 2 new biosimilars on the market, a bevacizumab and an interchangeable ranibizumab; Amneal Pharmaceuticals filed for marketing authorization in Europe; and Sandoz released positive results for a denosumab candidate.

Phase 3 Study of Amgen Biosimilar to Eculizumab Meets Primary End Points

August 24th 2022

By Mary Caffrey

Article

Eculizumab is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare bone marrow disorder in which expansion of certain hematopoietic cells that lack a key protein cause the destruction of red blood cells, or hemolysis.